Stock analysts at BTIG Research started coverage on shares of Misonix (NASDAQ:MSON) in a research report issued to clients and investors on Wednesday, Briefing.com Automated Import reports. The firm set a “buy” rating and a $29.00 price target on the medical equipment provider’s stock. BTIG Research’s price target would suggest a potential upside of 21.04% from the company’s current price.
Shares of MSON opened at $23.96 on Wednesday. Misonix has a 12 month low of $12.20 and a 12 month high of $26.41.
Misonix (NASDAQ:MSON) last released its earnings results on Wednesday, May 8th. The medical equipment provider reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.01. Misonix had a negative return on equity of 29.13% and a negative net margin of 18.10%. The company had revenue of $9.56 million during the quarter.
Large investors have recently made changes to their positions in the company. Vanguard Group Inc. raised its position in Misonix by 15.7% during the 3rd quarter. Vanguard Group Inc. now owns 213,040 shares of the medical equipment provider’s stock worth $3,941,000 after buying an additional 28,889 shares during the last quarter. Vanguard Group Inc grew its stake in Misonix by 15.7% in the 3rd quarter. Vanguard Group Inc now owns 213,040 shares of the medical equipment provider’s stock valued at $3,941,000 after acquiring an additional 28,889 shares during the last quarter. Acadian Asset Management LLC grew its stake in Misonix by 15.7% in the 4th quarter. Acadian Asset Management LLC now owns 9,504 shares of the medical equipment provider’s stock valued at $153,000 after acquiring an additional 1,292 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Misonix by 5.3% in the 4th quarter. Geode Capital Management LLC now owns 35,095 shares of the medical equipment provider’s stock valued at $561,000 after purchasing an additional 1,775 shares in the last quarter. Finally, Tibra Equities Europe Ltd purchased a new position in shares of Misonix during the 1st quarter worth about $327,000. 21.17% of the stock is currently owned by hedge funds and other institutional investors.
Misonix, Inc, together with its subsidiaries, designs, develops, manufactures, and markets therapeutic ultrasonic medical devices in the United States, the Americas, Europe, Middle East, Asia Pacific, Africa, and internationally. The company offers BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting of bone while sparing soft tissue; SonaStar, a surgical aspirator that is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleansing and debridement system, which provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells.
See Also: Yield Curve
Receive News & Ratings for Misonix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Misonix and related companies with MarketBeat.com's FREE daily email newsletter.